Navigation Links
FDA Accepts Sanofi Pasteur's Application to Expand Indication of Menactra® Vaccine to Infants and Toddlers
Date:8/26/2010

cination, as well as irritability.  Most of these side effects were mild and of short duration.

"Sanofi Pasteur is committed to evaluating Menactra vaccine in different age groups in an effort to provide the broadest protection against meningococcal disease," said Michael Decker, MD, MPH, vice president, scientific and medical affairs at sanofi pasteur. "Sanofi Pasteur's meningococcal vaccination approach, focusing on later infancy and the early second year of life, will require only half the doses of an early infant toddler strategy."

About Menactra® VaccineMenactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) is the only U.S. licensed conjugate vaccine for persons two through 55 years of age for active immunization against invasive meningococcal disease caused by N meningitidis serogroups A, C, Y, and W-135.  Since 2005 when it was first licensed in the U.S., more than 32 million doses of Menactra vaccine have been distributed.

A vaccine industry leader, Sanofi Pasteur has a strong heritage of meningococcal vaccine development.  Meningococcal vaccines designed to help protect against serogroups A and C were introduced in the mid-1970s.  In 1981, Menomune®-A/C/Y/W-135 (Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined) became the first meningococcal vaccine available to help protect against meningococcal disease caused by four of the five most common serogroups (A, C, Y and W-135).

In 2005, Menactra vaccine was granted FDA licensure and became the first quadrivalent meningococcal conjugate vaccine available in the U.S. for those 11-55 years of age.  Two years later the age indication was extended down to the age of two years.

Side effects following administration of Menactra vaccine include: pain, redness, and swelling at the injection site, as well as headache and fatigue.  Other side effects may
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
2. FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review
3. FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
4. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
5. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
6. FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
7. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
10. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
11. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Lumin Medical LLC, a healthcare IT provider, ... leading provider of on-demand patient tracking solutions and is ... to Franklin, Wis. ... and our mission is to provide visibility for the ... reduce costs," said James Hermann , President of ...
(Date:7/14/2014)... DIEGO , July 14, 2014  More than any ... their smartphones and tablet computers -- but their eyes don,t. ... have never needed before, and the eye has not evolved ... and what our eyes can do comfortably often results in ... collectively known as Digital Eye Strain. Now ZEISS has invented ...
(Date:7/14/2014)... EAGAN, Minn. , July 14, 2014  Today, ... Partners, announced that it acquired the assets of MicroTest ... MA.  The acquisition of MTL is the first step ... and chemistry laboratory services platform to support the medical ... be known as Accuratus Lab Services , a ...
Breaking Medicine Technology:Lumin Medical Purchases PatientTrak 2Lumin Medical Purchases PatientTrak 3New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 3
... III Study for the Treatment of Advanced Prostate CancerPARSIPPANY, ... launch of a Phase IIIB clinical trial of degarelix ... antagonist approved by the U.S. Food and Drug Administration ... cancer. The announcement was made at ...
... Diagnostic ToolSUNNYVALE, Calif., April 27 Cepheid (Nasdaq: ... MTB/RIF as a CE IVD Mark product under the ... Devices. For the first time, European clinicians will have ... Mycobacterium tuberculosis (MTB) and resistance to rifampicin ...
Cached Medicine Technology:Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 2Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 3Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 4Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6
(Date:7/14/2014)... Tysons, VA (PRWEB) July 14, 2014 ... been a local icon to the Tysons Corner skyline ... Corner becoming its own municipality, known simply as “Tysons”, ... Sheraton Tysons Hotel. In addition to Tysons becoming ... Stations located in the heart of Tysons brings an ...
(Date:7/14/2014)... TX (PRWEB) July 14, 2014 Kenn Renner ... recently. The video is meant to describe the business on ... estate broker and national speaker – Kenn Renner – is ... branding, marketing, and goal setting techniques. , Investing in real ... money. Some people do it as their career, while others ...
(Date:7/14/2014)... 2014 Dry eyes, contrary to popular opinion, ... recent research have pointed out, today’s technology has practically enabled ... as a result of using laptops and smartphones to ... Because of this phenomenon, it has become imperative for people ... cure them from having dry eyes, but prevent it from ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 The Cabin ... launched its new Alumni Community website – ... treatment, to help them maintain lifelong recovery wherever they ... that providing clients the tools to help them maintain ... and essential part of any reputable treatment programme. As ...
(Date:7/14/2014)... July 14, 2014 EurekaMag.com has newly ... which is a contagious liver disease that ranges ... weeks to a serious, lifelong illness that attacks the ... States have chronic Hepatitis C virus infection of which ... site's research category covers all studies on Hepatitis ...
Breaking Medicine News(10 mins):Health News:Iconic Tyson’s Corner Hotel Embraces the New “Tysons” Evolution 2Health News:Iconic Tyson’s Corner Hotel Embraces the New “Tysons” Evolution 3Health News:Iconic Tyson’s Corner Hotel Embraces the New “Tysons” Evolution 4Health News:Dry Eye Handbook Review | Taking Care of One’s Vision by Using Natural Methods – Vinamy.com 2Health News:Dry Eye Handbook Review | Taking Care of One’s Vision by Using Natural Methods – Vinamy.com 3Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:EurekaMag.com Publishes 64,900 New Studies on Hepatitis C 2
... off from certain osteoporosis drugs may be beneficial to bone ... System. Researchers found that bone density remained stable for three ... a popular class of osteoporosis drugs that can cause fractures ... bone. "These drugs are potentially harmful when taken for ...
... By Randy Dotinga HealthDay Reporter , THURSDAY, Nov. ... evidence that people infected with HIV, the virus that causes ... other patients when they undergo kidney transplants. Up until ... HIV patients because of fear that AIDS would quickly kill ...
... Johns Hopkins have identified a compound that could be ... The compound, called a glutaminase inhibitor, has been ... scientists say, may have the potential to be used ... Johns Hopkins scientists, are inventors on patent applications related ...
... NC Researchers have been stymied for years over the ... produce antibodies in response to the pathogen antibodies that ... at Duke University Medical Center can explain why: Some of ... can,t actually "see" the virus until after it,s already invaded ...
... THURSDAY, Nov. 18 (HealthDay News) -- Millions of harried ... indoor smoking at one in every four major U.S. ... smoke-free policies at large-hub airports in 2002 and 2010 ... nation,s largest airports, including three of the five busiest: ...
... Reinberg HealthDay Reporter , WEDNESDAY, Nov. 17 (HealthDay ... example, new research finds that doctors, prescribing patterns vary across ... U.S. Food and Drug Administration. The result is ... depending on where they live, the researchers said. "We ...
Cached Medicine News:Health News:Taking a break from osteoporosis drugs can protect bones 2Health News:HIV Patients Do Well After Kidney Transplants: Study 2Health News:HIV Patients Do Well After Kidney Transplants: Study 3Health News:Compound that blocks sugar pathway slows cancer cell growth 2Health News:Compound that blocks sugar pathway slows cancer cell growth 3Health News:Why so many antibodies fail to protect against HIV infection 2Health News:Smoking Still Allowed at 1 in 4 Major U.S. Airports 2Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 2Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 3
... a low osmolar ionic dimer. Each ... meglumine, 196 mg of ioxaglate sodium ... disodium as a stabilizer. The solution ... each milliliter and provides 32% (320 ...
... IMAGOPAQUE is a non-ionic monomeric contrast ... in adults and children. After a decade ... 3.5 million examinations, IMAGOPAQUE has proven to ... effort in hundreds of radiology departments.Results from ...
... is a liver-specific contrast agent approved for ... Its introduction expands the Amersham Health portfolio ... injected intravenously, TESLASCAN aids in the detection, ... Imaging can begin within minutes of injection, ...
... a new Contrast Agent for ... of stabilized SF6 microbubbles. The ... between 1 and 10 m, ... 2 and 5 x 108 ...
Medicine Products: